Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab plus pembrolizumab in adults with non-small cell lung cancer
NL-OMON61039Phase 2Completed
- Sponsor
- Merus
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of petosemtamab and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merus. Primary endpoint: Objective response rate. Started May 2026; status: completed.
02
Drugs
petosemtamabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61039.